Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission

Background: Perinatal human immunodeficiency virus (HIV) prevention programs have been implemented in several countries, and many children have been or will be exposed to antiretrovirals in utero and during their first weeks of life. Although reducing substantially the number of infected children, t...

Full description

Saved in:
Bibliographic Details
Main Authors: Nelly Briand, Sophie Le Coeur, Patrinee Traisathit, Varit Karnchanamayul, Rawiwan Hansudewechakul, Chaiwat Ngampiyasakul, Sorakit Bhakeecheep, Jeerapahan Ithisukanan, Suchat Hongsiriwon, Kenneth Mclntosh, Marc Lallemant
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33645550495&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61886
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-61886
record_format dspace
spelling th-cmuir.6653943832-618862018-09-11T09:00:45Z Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission Nelly Briand Sophie Le Coeur Patrinee Traisathit Varit Karnchanamayul Rawiwan Hansudewechakul Chaiwat Ngampiyasakul Sorakit Bhakeecheep Jeerapahan Ithisukanan Suchat Hongsiriwon Kenneth Mclntosh Marc Lallemant Medicine Background: Perinatal human immunodeficiency virus (HIV) prevention programs have been implemented in several countries, and many children have been or will be exposed to antiretrovirals in utero and during their first weeks of life. Although reducing substantially the number of infected children, the potential adverse consequences of these treatments on the health of HIV-uninfected children need to be assessed. Objective: To investigate the impact of in utero and postnatal zidovudine exposure on the growth of HIV-uninfected children born to HIV-infected women. Methods: We used data prospectively collected in 1408 live born children participating in a clinical trial comparing zidovudine regimens of different durations to prevent perinatal transmission in Thailand (PHPT-I). We used a linear mixed model to analyze the anthropometric measurements (weight for age, height for age and weight for height Z-scores) until 18 months of age according to zidovudine treatment duration (mothers, <7.5 weeks versus more; infants, 3 days versus >4 weeks). Results: Children exposed in utero for >7.5 weeks had a slightly lower birth weight (Z-score difference, 0.08; P = 0.003). However, zidovudine exposure had no effect on the evolution of Z-scores from 6 weeks to 18 months of age. Conclusions: Although a longer in utero zidovudine exposure may have had a negative impact on birth weight, the magnitude of this effect was small and faded over time. Neither the total nor the postnatal duration of exposure was associated with changes in infant Z-scores from 6 weeks to 18 months of age. Copyright © 2006 by Lippincott Williams & Wilkins. 2018-09-11T09:00:45Z 2018-09-11T09:00:45Z 2006-04-01 Journal 08913668 2-s2.0-33645550495 10.1097/01.inf.0000207398.10466.0d https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33645550495&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61886
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Nelly Briand
Sophie Le Coeur
Patrinee Traisathit
Varit Karnchanamayul
Rawiwan Hansudewechakul
Chaiwat Ngampiyasakul
Sorakit Bhakeecheep
Jeerapahan Ithisukanan
Suchat Hongsiriwon
Kenneth Mclntosh
Marc Lallemant
Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
description Background: Perinatal human immunodeficiency virus (HIV) prevention programs have been implemented in several countries, and many children have been or will be exposed to antiretrovirals in utero and during their first weeks of life. Although reducing substantially the number of infected children, the potential adverse consequences of these treatments on the health of HIV-uninfected children need to be assessed. Objective: To investigate the impact of in utero and postnatal zidovudine exposure on the growth of HIV-uninfected children born to HIV-infected women. Methods: We used data prospectively collected in 1408 live born children participating in a clinical trial comparing zidovudine regimens of different durations to prevent perinatal transmission in Thailand (PHPT-I). We used a linear mixed model to analyze the anthropometric measurements (weight for age, height for age and weight for height Z-scores) until 18 months of age according to zidovudine treatment duration (mothers, <7.5 weeks versus more; infants, 3 days versus >4 weeks). Results: Children exposed in utero for >7.5 weeks had a slightly lower birth weight (Z-score difference, 0.08; P = 0.003). However, zidovudine exposure had no effect on the evolution of Z-scores from 6 weeks to 18 months of age. Conclusions: Although a longer in utero zidovudine exposure may have had a negative impact on birth weight, the magnitude of this effect was small and faded over time. Neither the total nor the postnatal duration of exposure was associated with changes in infant Z-scores from 6 weeks to 18 months of age. Copyright © 2006 by Lippincott Williams & Wilkins.
format Journal
author Nelly Briand
Sophie Le Coeur
Patrinee Traisathit
Varit Karnchanamayul
Rawiwan Hansudewechakul
Chaiwat Ngampiyasakul
Sorakit Bhakeecheep
Jeerapahan Ithisukanan
Suchat Hongsiriwon
Kenneth Mclntosh
Marc Lallemant
author_facet Nelly Briand
Sophie Le Coeur
Patrinee Traisathit
Varit Karnchanamayul
Rawiwan Hansudewechakul
Chaiwat Ngampiyasakul
Sorakit Bhakeecheep
Jeerapahan Ithisukanan
Suchat Hongsiriwon
Kenneth Mclntosh
Marc Lallemant
author_sort Nelly Briand
title Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
title_short Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
title_full Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
title_fullStr Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
title_full_unstemmed Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
title_sort growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33645550495&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61886
_version_ 1681425704256798720